The HemOnc Pulse Holding the Line in AML: Real-World Care Meets Breakthrough Trials
Dec 20, 2025
Dr. Eunice Wang, a leading expert in AML and chief of the leukemia service at Roswell Park, joins Dr. Rahul Banerjee for a deep dive into the complexities of leukemia treatment. They discuss the biology and risk profile of NPM1, and how menin inhibitors function, shedding light on the COMET-001 trial for ziftomenib. With a 33% response rate, Wang highlights its promise in treating relapsed AML. The duo also explores combinations of ziftomenib with other therapies, and details the importance of differentiating syndrome management in practice.
AI Snips
Chapters
Transcript
Episode notes
Shared Biology Between NPM1 And KMT2A Leukemias
- NPM1-mutant AML behaves like favorable risk with frontline intensive chemo but shares biology with KMT2A-rearranged leukemias.
- Menin inhibitors target a shared menin–transcription complex to reverse differentiation block in both disease types.
Ziftomenib Shows Meaningful Activity In R/R NPM1 AML
- In the COMET-1 registration cohort, ziftomenib produced a 33% overall response in heavily pretreated NPM1-mutant R/R AML.
- Median duration of response was 4.6 months and overall survival about six months, exceeding historic controls.
Act Early For Differentiation Syndrome
- Monitor for differentiation syndrome early, especially within the first 14 days of menin inhibitor therapy.
- Stop drug and treat with steroids if symptoms don't improve and follow the trial algorithm for grade escalation.